LON:HIKHikma Pharmaceuticals Share Price, Forecast & News

GBX 2,342

-50.00 (-2.09 %)

(As of 06/5/2020 08:02 AM ET)

Add

Compare

Today's Range

2,319

Now: GBX 2,342▼

2,392

50-Day Range

2,230

MA: GBX 2,419.74▼

2,575

52-Week Range

1,574.50

Now: GBX 2,342▼

2,670

Volume227,252 shs

Average Volume822,138 shs

Market Capitalization£5.70 billion

P/E Ratio15.74

Dividend Yield2.00%

BetaN/A

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including oncology and anti-viral products to hospitals. The Generics segment develops and sells oral and other non-injectable generic products for retail market. The Branded segment develops, manufactures, and markets branded generics and in-licensed products to retail and hospital markets. The company offers products in various therapeutic areas, including respiratory, oncology, pain management, anti-infectives, cardiovascular, diabetes, and central nervous system. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Beat the Market (BTM) Rank^™

2.2 Analyst's Opinion

Consensus Rating
Hikma Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 4 buy ratings, 3 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of GBX 2,378.33, Hikma Pharmaceuticals has a potential upside of 1.6% from its current price of GBX 2,342.
Amount of Analyst Coverage
Hikma Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.8 Community Rank

Outperform Votes
Hikma Pharmaceuticals has received 758 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Hikma Pharmaceuticals has received 619 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Hikma Pharmaceuticals has received 55.05% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Hikma Pharmaceuticals and other stocks. Vote “Outperform” if you believe HIK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HIK will underperform the S&P 500 over the long term. You may vote once every thirty days.

2.5 Dividend Strength

Dividend Leadership
Hikma Pharmaceuticals is a leading dividend payer. It pays a dividend yield of 2.00%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Hikma Pharmaceuticals does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Hikma Pharmaceuticals is 32.26 %. This payout ratio is at a healthy, sustainable level, below 75%.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Hikma Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought GBX 0 in company stock and sold £33,075,000 in company stock.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Hikma Pharmaceuticals are expected to decrease by -100.00% in the coming year, from GBX 134 to GBX 0 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Hikma Pharmaceuticals is 15.74, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 15.96.
Price to Earnings Ratio vs. Sector
The P/E ratio of Hikma Pharmaceuticals is 15.74, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.64.
Price to Book Value per Share Ratio
Hikma Pharmaceuticals has a P/B Ratio of 3.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.75 out of 5 stars

Industry, Sector and Symbol

Stock Exchange LON

Industry Drug Manufacturers - Specialty & Generic

Sub-IndustryN/A

SectorMedical

Current SymbolLON:HIK

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.hikma.com

Phone+44-20-73992760

Debt

Debt-to-Equity Ratio37.69

Current Ratio1.28

Quick Ratio0.78

Price-To-Earnings

Trailing P/E Ratio15.74

Forward P/E Ratio17.48

P/E GrowthN/A

Sales & Book Value

Annual Sales£2.14 billion

Price / Sales2.66

Cash FlowGBX 139.03 per share

Price / Cash Flow16.85

Book ValueGBX 756.30 per share

Price / Book3.10

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Employees8,400

Outstanding Shares243,168,992

Market Cap£5.70 billion

Next Earnings Date8/7/2020 (Estimated)

OptionableNot Optionable

Receive HIK News and Ratings via Email

Sign-up to receive the latest news and ratings for HIK and its competitors with MarketBeat's FREE daily newsletter.

Hikma Pharmaceuticals (LON:HIK) Frequently Asked Questions

How has Hikma Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Hikma Pharmaceuticals' stock was trading at GBX 1,828.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, HIK stock has increased by 28.1% and is now trading at GBX 2,342. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Hikma Pharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Hikma Pharmaceuticals.

When is Hikma Pharmaceuticals' next earnings date?

Hikma Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 7th 2020. View our earnings forecast for Hikma Pharmaceuticals.

How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals?

Hikma Pharmaceuticals declared a dividend on Thursday, February 27th. Shareholders of record on Thursday, March 19th will be given a dividend of GBX 0.30 per share on Thursday, May 7th. This represents a dividend yield of 1.22%. The ex-dividend date is Thursday, March 19th. This is an increase from Hikma Pharmaceuticals's previous dividend of GBX 0.14. The official announcement can be accessed at this link. View Hikma Pharmaceuticals' dividend history.

What price target have analysts set for HIK?

8 analysts have issued 12 month price targets for Hikma Pharmaceuticals' stock. Their forecasts range from GBX 2,200 to GBX 2,500. On average, they anticipate Hikma Pharmaceuticals' stock price to reach GBX 2,378.33 in the next twelve months. This suggests a possible upside of 1.6% from the stock's current price. View analysts' price targets for Hikma Pharmaceuticals.

Has Hikma Pharmaceuticals been receiving favorable news coverage?

Media headlines about HIK stock have trended extremely negative recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Hikma Pharmaceuticals earned a media sentiment score of -5.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutHikma Pharmaceuticals.

Who are some of Hikma Pharmaceuticals' key competitors?

Some companies that are related to Hikma Pharmaceuticals include Merck KGaA (MRK), Bausch Health Companies (BHC), Canopy Growth (WEED), Evotec (EVT), Aurora Cannabis (ACB), Aphria (APHA), Knight Therapeutics (GUD), Ecofibre (EOF), HLS Therapeutics (HLS), OrganiGram (OGI), Hexo (HEXO), Next Science (NXS), HEXO (HEXO), ICC Labs (ICC) and Amryt Pharma (AMYT). View all competitors.

What other stocks do shareholders of Hikma Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hikma Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Gran Tierra Energy (GTE), Och-Ziff Capital Management Group (OZM) and Belden (BDC).

Who are Hikma Pharmaceuticals' key executives?

Hikma Pharmaceuticals' management team includes the following people:

Mr. Said Samih Taleb Darwazah, Exec. Chairman (Age 62)
Mr. Mazen Samih Taleb Darwazah, Exec. Vice Chairman & Pres of MENA (Age 61)
Mr. Sigurdur Oli Olafsson Ph.D., CEO & Exec. Director (Age 50)
Mr. Khalid Walid Hussni Nabilsi, Chief Financial Officer (Age 47)
Dr. Surendera Tyagi, Group Chief Scientific Officer and Global Head of R&D

What is Hikma Pharmaceuticals' stock symbol?

Hikma Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "HIK."

How do I buy shares of Hikma Pharmaceuticals?

Shares of HIK and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Hikma Pharmaceuticals' stock price today?

One share of HIK stock can currently be purchased for approximately GBX 2,342.

How big of a company is Hikma Pharmaceuticals?

Hikma Pharmaceuticals has a market capitalization of £5.70 billion and generates £2.14 billion in revenue each year. Hikma Pharmaceuticals employs 8,400 workers across the globe.

What is Hikma Pharmaceuticals' official website?

The official website for Hikma Pharmaceuticals is www.hikma.com.

How can I contact Hikma Pharmaceuticals?

Hikma Pharmaceuticals' mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The company can be reached via phone at +44-20-73992760.

This page was last updated on 6/5/2020 by MarketBeat.com Staff